OnCo
ideasIdea

Build laboratory models of the organs cancer spreads to

Cancer usually kills by spreading to bone, liver, lung or brain. Almost all laboratory models grow tumours under the skin instead, where the surroundings are nothing like those organs.

Subcutaneous xenografts remain the default despite being the least relevant site. Engineered bone marrow niches, liver-on-chip with resident macrophages, and perfused lung and brain models can be seeded with patient tumour cells to study colonisation, dormancy and organ-specific drug response. Organ-specific microenvironments determine both seeding and treatment sensitivity.

Hypothesis
Drug sensitivity of the same tumour cells differs substantially between organ-mimicking niches, and niche-specific results predict site-specific clinical response better than subcutaneous models.
Rationale
Clinically, responses differ by metastatic site (for example liver metastases predict poor immunotherapy benefit), which no subcutaneous model can represent.
What would test it
Test three agents against matched tumour cells in bone, liver and lung niche models and compare with site-specific response data from clinical imaging cohorts.
Maturity
speculative
Who has to act
engineering
Cost to try
Medium ($1M to $50M)
Years to first evidence
5
Bottlenecks it attacks

Connected

5top

Pages like this

not linked directly; found by shared links